BioVaxys Technology (BioVaxys Technology) Total Stockholders Equity : $-0.47 Mil (As of Jul. 2023)

View and export this data going back to 2018. Start your Free Trial

What is BioVaxys Technology Total Stockholders Equity?

BioVaxys Technology's Total Stockholders Equity for the quarter that ended in Jul. 2023 was $-0.47 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. BioVaxys Technology's Book Value per Share for the quarter that ended in Jul. 2023 was $-0.00. The ratio of a company's debt over equity can be used to measure how leveraged this company is. BioVaxys Technology's Debt-to-Equity for the quarter that ended in Jul. 2023 was 0.00.

BioVaxys Technology Total Stockholders Equity Historical Data

The historical data trend for BioVaxys Technology's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioVaxys Technology Total Stockholders Equity Chart

BioVaxys Technology Annual Data

Trend

Oct18

Oct19

Oct20

Oct21

Oct22

Total Stockholders Equity

-0.06

0.14

7.23

6.58

-0.57

BioVaxys Technology Quarterly Data
	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23
Total Stockholders Equity	Get a 7-Day Free Trial															4.79	-0.57	-0.46	0.67	-0.47

BioVaxys Technology (OTCPK:BVAXF) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

BioVaxys Technology's Book Value per Share for the quarter that ended in Jul. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(-0.472	-	0)	/	145.112
	=	-0.00

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

BioVaxys Technology's Debt-to-Equity for the quarter that ended in Jul. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	-0.472
	=	0.00

BioVaxys Technology Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of BioVaxys Technology's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

BioVaxys Technology (BioVaxys Technology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVaxys Technology Corp (OTCPK:BVAXF) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

5LB:Germany BIOV:Canada

Address

146 Thirtieth Street, Suite 100, Etobicoke, ON, CAN, M8W 3D4

Website

https://www.biovaxys.com

BioVaxys Technology Corp is a clinical-stage biopharma company. The company develops antiviral and anticancer vaccine platforms to treat SARS-CoV-2 and other viral infections, as well as ovarian cancer and other solid tumor types.